| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Piromidic acid targets bacterial DNA gyrase, a type II topoisomerase essential for bacterial DNA replication. By inhibiting DNA gyrase, the compound prevents the supercoiling of bacterial DNA, leading to the inhibition of DNA replication and transcription. This results in the death of bacterial cells. The compound shows activity against Gram-negative bacteria and Staphylococcus aureus.
|
|---|---|
| ln Vitro |
In vitro, piromidic acid exhibits antibacterial activity against a range of Gram-negative organisms. It also shows activity against Staphylococcus aureus. The compound's mechanism of action involves inhibition of bacterial DNA synthesis. Minimum inhibitory concentrations (MICs) vary depending on the bacterial strain. Detailed in vitro activity data is available in the primary literature.
|
| ln Vivo |
In vivo, piromidic acid is used clinically for the treatment of urinary tract and intestinal infections. It has also been utilized for biliary tract infections. The compound's antibacterial activity is attributed to its inhibition of bacterial DNA gyrase. Specific in vivo efficacy data and dosing regimens are described in the clinical literature.
|
| Enzyme Assay |
Non-cellular enzyme assays for piromidic acid involve measuring DNA gyrase inhibition. The enzyme is incubated with DNA substrate and varying concentrations of the compound. DNA supercoiling or relaxation activity is measured by agarose gel electrophoresis. IC₅₀ values are calculated from inhibition curves.
|
| Cell Assay |
In vitro cellular experiments involve culturing bacterial strains (Gram-negative and Staphylococcus aureus) in the presence of piromidic acid. Antibacterial activity is assessed by measuring the minimum inhibitory concentration (MIC) using broth dilution or agar diffusion methods. Bacterial growth is monitored by optical density measurements.
|
| Animal Protocol |
In vivo animal studies for piromidic acid would involve infection models in rodents. Animals are infected with pathogenic bacteria and treated with piromidic acid via oral or parenteral routes. Bacterial clearance from tissues is assessed by colony counting. Survival and clinical signs are monitored.
|
| ADME/Pharmacokinetics |
Piromidic acid is administered orally. It has a molecular weight of 288.30 g/mol and a molecular formula of C₁₄H₁₆N₄O₃. The compound has a pKa of 3.27 and 6.54. It is absorbed from the gastrointestinal tract and excreted through the kidneys.
|
| Toxicity/Toxicokinetics |
Piromidic acid is generally well-tolerated. As an antibacterial agent, it may cause gastrointestinal effects. Specific toxicity data is limited in publicly available sources. The compound is for research purposes only and should be handled with appropriate safety precautions.
|
| References | |
| Additional Infomation |
Piromidic acid is a pyridopyrimidine compound, chemically named 5-oxo-5,8-dihydropyrido[2,3-d]pyrimidine-6-carboxylic acid, with a pyrrolidine-1-yl substituted at the 2-position and an ethyl substituted at the 8-position. It is a synthetic antibacterial drug used to treat urinary tract and intestinal infections. Piromidic acid has dual antibacterial and DNA synthesis-inhibiting effects. It is a quinolone antibiotic, belonging to the pyrrolidine class of compounds, a tertiary amine compound, and also a monocarboxylic acid and pyridopyrimidine compound. Piromidic acid is a quinolone antibiotic effective against Gram-negative bacteria. Piromidic acid is used to treat urinary tract and intestinal infections. Its main antibacterial effect is against Gram-negative bacteria. It is used to treat urinary tract and intestinal infections.
Piromidic acid is a synthetic antibacterial agent active against Gram-negative bacteria and Staphylococcus aureus. It is used for the treatment of urinary tract, intestinal, and biliary tract infections. The compound inhibits bacterial DNA gyrase, preventing DNA replication and transcription. This product is for research purposes only and is not for human therapeutic use. |
| Molecular Formula |
C14H16N4O3
|
|---|---|
| Molecular Weight |
288.31
|
| Exact Mass |
288.122
|
| CAS # |
19562-30-2
|
| PubChem CID |
4855
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.4g/cm3
|
| Boiling Point |
504ºC at 760mmHg
|
| Flash Point |
258.6ºC
|
| Vapour Pressure |
5.58E-11mmHg at 25°C
|
| Index of Refraction |
1.633
|
| LogP |
1.174
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
21
|
| Complexity |
473
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
RCIMBBZXSXFZBV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H16N4O3/c1-2-17-8-10(13(20)21)11(19)9-7-15-14(16-12(9)17)18-5-3-4-6-18/h7-8H,2-6H2,1H3,(H,20,21)
|
| Chemical Name |
8-ethyl-5-oxo-2-pyrrolidin-1-ylpyrido[2,3-d]pyrimidine-6-carboxylic acid
|
| Synonyms |
Actrun C; Acidum piromidicum [INN-Latin]; Piromidic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~1 mg/mL (~3.47 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4685 mL | 17.3424 mL | 34.6849 mL | |
| 5 mM | 0.6937 mL | 3.4685 mL | 6.9370 mL | |
| 10 mM | 0.3468 mL | 1.7342 mL | 3.4685 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
